Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$1.02B+482.80%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brandon K. Sim
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 3,000
- Beta
- 0.91
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.70
Financials
Revenue
$1.02B+482.8%Net Income
$12.95M+2.3%EBITDA
$62.87M-30.6%Free Cash Flow
$12.44M-11.6%EPS (diluted)
$0.26-7.1%Shares Outstanding (diluted)
49.92M+8.9%Operating Expenses
$68.05MCash & Debt
$396.23MReturn of Capital
$2.02MRevenue by Segment (annual)
$3.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.18B | $22.49M | $0.46 |
| 2024 | $2.03B | $43.15M | $0.91 |
| 2023 | $1.39B | $60.72M | $1.30 |
| 2022 | $1.14B | $45.17M | $1.00 |
| 2021 | $773.91M | $68.92M | $1.57 |
| 2020 | $370.25M | $-23.75M | $1.04 |
| 2019 | $560.62M | $14.12M | $0.41 |
| 2018 | $519.91M | $10.84M | $0.33 |
| 2017 | $357.75M | $25.80M | $1.01 |
| 2015 | $44.05M | $-9.34M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.67
- Implied price
- $36.36
- Return from $28.90
- 4.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $18.08 — -37.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 38 | 46 | 54 | 62 | 70 |
|---|---|---|---|---|---|
| -2.0% | -11.4% | -8.0% | -5.0% | -2.3% | 0.1% |
| 3.0% | -6.9% | -3.3% | -0.1% | 2.6% | 5.2% |
| 8.0% | -2.4% | 1.4% | 4.7% | 7.6% | 10.3% |
| 13.0% | 2.1% | 6.1% | 9.5% | 12.6% | 15.4% |
| 18.0% | 6.6% | 10.8% | 14.4% | 17.6% | 20.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (12)
- Newsseekingalpha.com·16d ago·Positive
Astrana Health, Inc. (ASTH) Q3 2026 Earnings Call Transcript Astrana Health, Inc. ( ASTH ) Q3 2026 Earnings Call November 5, 2026 5:30 PM EST Company Participants Brandon Sim - President & CEO Chan Basho - CFO, COO & Corporate Secretary Conference Call Participants Jack Slevin - Jefferies LLC, Research Division Hua Ha - Robert W. Baird & Co. Incorporated, Research Division Andrew Mok - Barclays Bank PLC, Research Division Ryan Langston - TD Cowen, Research Division Matthew Gillmor - KeyBanc Capi…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Astrana Health Q3 Earnings Call Highlights Astrana Health NASDAQ: ASTH reported record third-quarter revenue and adjusted EBITDA as growth in Medicare Advantage membership and full-risk contracts helped offset declines in Medicaid and exchange enrollment.
View source ↗ - Newszacks.com·17d ago·Negative
Astrana Health, Inc. (ASTH) Q3 Earnings Lag Estimates Astrana Health, Inc. (ASTH) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.01 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
Astrana Health, Inc. Reports Third Quarter 2026 Results Company to Host Conference Call on Thursday, November 5, 2026, at 2:30 p.m. PT/5:30 p.m.
View source ↗ - Newsseekingalpha.com·25d ago·Negative
Diamond Hill Small Cap Fund Q3 2026 Portfolio Activity Utz Brands shares rose after entering into an agreement to be acquired by Intersnack, a privately held European leader in savory snacks. Shares of health care management company Astrana Health declined during the quarter as selling pressure emerged following a strong first half of 2026. We initiated a position in Bank7, given its highly profitable, branch-light model and recent acquisition of Century Bank, which we believe should meaningfull
View source ↗ - Newsgurufocus.com·44d ago·Positive
Is It Too Late to Buy Astrana Health Inc (ASTH) After 4.7% Rally? GF Value Says Undervalued On October 09, 2026, Astrana Health Inc (ASTH) shares rose 4.7% to a current price of $37.55, within a 52-week range of $18.08 to $51.60. This movement reflects
View source ↗ - Newsprnewswire.com·44d ago·Neutral
…l ALHAMBRA, Calif., Oct. 9, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the third quarter ended September 30, 2026, after the close of the stock market on Thursday, November 5, 2026.
View source ↗ - Newszacks.com·44d ago·Neutral
Why Astrana Health, Inc. (ASTH) is Poised to Beat Earnings Estimates Again Astrana Health, Inc. (ASTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newsbusinesswire.com·55d ago·Negative
ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ASTH--ASTH Investors Have Opportunity to Join Astrana Health, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsbusinesswire.com·58d ago·Negative
PRIVACY ALERT: AWKO Law Investigating Astrana Health Data Breach SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of individuals affiliated with Astrana Health, Inc.'s subsidiary, Astrana Health Management, Inc. Astrana Health, Inc. is a California-based technology-powered healthcare company that operates as a Management Services Organization (MSO). On September 23, 2026, Astrana Health, Inc. disclosed to the
View source ↗ - Newsglobenewswire.com·61d ago·Neutral
Lowey Dannenberg, P.C. is Investigating Astrana Health, Inc. (NASDAQ: ASTH) for Potential Violations of the Federal Securities Laws NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Astrana Health: 81% Full-Risk And Profitable Astrana Health is rated a buy, trading at a 46% discount to peers despite sector-wide reserve releases clarifying earnings quality concerns. ASTH's Care Enablement platform drove G&A costs from 7.75% to 5.57% of revenue, quadrupling third-party revenue year-over-year and supporting durable profit at scale. Organic growth is driven by a mix-shift into full-risk capitation, with management projecting ongoing revenue-per-member expansion and a robust con
View source ↗
Earnings
Mon, Mar 1(in 3 months)
Consensus estimate $0.16 per share
Typical surprise -20.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.71 vs $0.46beat
- Thu, Aug 6$0.40 vs $0.34beat
- Thu, May 7$0.30 vs $0.29beat
- Mon, Mar 2$0.12 vs $0.15miss
- Thu, Nov 6$0.01 vs $0.47miss
- Thu, Aug 7$0.19 vs $0.36miss
Estimates and results for ASTH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ASTH officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ASTH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
